Investor Presentaiton slide image

Investor Presentaiton

Globally since 2017, a Total of 34 CGT Therapies Have Received Their First- time Approval CGT drugs which obtained 1st time approval, including approvals from ex-US regulatory authorities since 2017 8 ■Cell therapy (non-gene-modified) Gene-modified cell therapy 7 Gene therapy 6 LO 4 3 2 1 0 LUXTURNA GINTUIT Delytact Abecma ADSTILADRIN skysona Upstaza Elevidys Relma-cel HEMGENIX Cetranacogene dezaparvovec-drib Vyjuvek KYMRIAH HPC cord blood YESCARTA (axicabtagene cila eucel) Stemirac Collategene libmeldy™ Breyanzi (atidarsagene autotemcel) OrthoACIT Stempeucel 2017 Source: Public information 2018 Rosmir zynteglo TECARTUS StrataGraft™ ALOFISEL zolgensma Nepic RETHYMIC™ 2019 2020 2021 2022 ROCTAVIAN Lantidra EBVALLO tabelecie cel CARVYKTI (citacabtagene autoleuce Omisirge® Vyznova ビズノバ 2023 ニ 药明康德 Wuxi AppTec
View entire presentation